EHA 2015: Pacritinib therapy led to myelofibrosis symptom improvement in patients without other medical options - 101271

Spotlight
Video

EHA 2015: Pacritinib therapy led to myelofibrosis symptom improvement in patients without other medical options

EMJ has 458 videos Subscribe Here

Loading........
Description: The phase 3 PERSIST-1 study showed that pacritinib, a selective inhibitor of Janus Kinase 2 (JAK2) and Fms-Like Tyrosine Kinase-3 (FLT3), is more effective than the best available therapy (BAT) at improving disease symptoms and quality of life (QoL) for patients with myelofibrosis. Patient-reported outcomes (PROs), which have become important for approval of new therapies, was also measured to determine whether pacritinib reduced patients’ symptom burden and helped them feel better.

Presented by Ruben Mesa, MD, FACP, Mayo Clinic, Scottsdale, AZ, at the 20th Congress of the European Hematology Association (EHA)

–––

European Medical Journal

Website: http://emjreviews.com/...
Twitter: https://twitter.com/EMJRevi...
Facebook: https://www.facebook.com/em...
Shared By : EMJ
Posted on : 06/15/15
Added : 3 years ago



Recommended

Nothing found.

More From EMJ

Nothing found.